Next Level Genomics Adds Oxford Nanopore's PromethION-24 Long-Read Sequencing Services in Singapore

April 17, 2024 10:01 PM AEST | By EIN Presswire
 Next Level Genomics Adds Oxford Nanopore's PromethION-24 Long-Read Sequencing Services in Singapore
Image source: EIN Presswire

Next Level Genomics, a Singapore long-read sequencing services provider, has added Oxford Nanopore Technologies to their PacBio and Nanostring genomics services

SINGAPORE, April 17, 2024 /EINPresswire.com/ -- Next Level Genomics Pte Ltd, a Singapore-based provider of advanced genomics services to researchers and clinician scientists, proudly announces the installation of the Oxford Nanopore Technologies’ PromethION-24 (P24) sequencer in its local NGS laboratory in Biopolis.

The PromethION-24 from ONT provides unparalleled flexibility in performing long-read sequencing across a wide range of sample types. By allowing up to 24 independent, simultaneous flow cell sequencing, Next Level Genomics is capable of generating data from whole human genomes, complete with epigenetic modification information, down to small genomes from viruses and microbes with rapid turn-around times for local researchers. Nanopore technology includes such unique capabilities as direct RNA sequencing and adaptive sampling for targeted sequencing of key areas of the genome without additional reagents and tools. Coupled with high performance computing power, Next Level Genomics is capable of analyzing genome data from multiple long-read sequencing technologies for researchers.

“We are excited to add Oxford Nanopore sequencing to our laboratory and service capabilities. This will allow Next Level Genomics to become the premiere service provider in long-read NGS sequencing with both Oxford Nanopore and PacBio Revio systems for use by the local research community and give more scientists the tools they need to advance their science and make new discoveries,” quoted David Klinzing, PhD, CTO for Next Level Genomics.

Next Level Genomics’ CEO Gregor Kent added: “Our local customers have expressed a clear need for direct access to the most appropriate tool for their Long-read NGS needs; for ready access to the actual lab and scientists running their samples; and the importance of keeping precious samples in Singapore for data safety, faster turn-around times, and general flexibility of experiment design.”

With the addition of the PromethION-24 sequencer, Next Level Genomics is poised to deliver comprehensive long-read sequencing solutions tailored to the unique requirements of each research project. The addition of this platform solidifies Next Level Genomics' commitment to advancing genomics research and empowering scientists with the latest technologies including Oxford Nanopore and PacBio for genome sequencing as well as Nanostring CosMx and GeoMx for spatial multiomics analysis.

About Next Level Genomics Pte Ltd (NLG): https://www.nextlevelgenomics.com/

Jovin Lee
Next Level Genomics Pte Ltd
+65 8822 6227
email us here
Visit us on social media:
LinkedIn
YouTube


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.